Radioactive drug trial offers hope for rare, untreatable tumors
NCT ID NCT03206060
Summary
This study is testing an experimental radioactive drug called Lu-177-DOTATATE for adults with rare adrenal or nerve-related tumors that cannot be removed by surgery. The main goals are to see if the treatment is safe and if it can help patients live longer without their cancer getting worse. Participants receive four doses of the drug through an IV over several months and are closely monitored with scans and check-ups for up to three years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.